The search for innovative anti-cancer drugs remains a challenge. Over the past three
decades, antibodies have emerged as an essential asset in successful cancer therapy. The …

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of
malignant and non-malignant disorders. CARs are synthetic transmembrane receptors …

Summary Background Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma
(HCC)-associated antigen and a promising target for HCC treatment. CT017 CAR T cells …

Osteosarcoma, the most common bone malignancy in children and adolescents, poses
considerable challenges in terms of prognosis, especially for patients with metastatic or …

Exosomes are nanoscale vesicles secreted by most cells and have a phospholipid bilayer
structure. Exosomes contain DNA, small RNA, proteins, and other substances that can carry …

Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …

The tumor microenvironment, particularly the immune microenvironment, plays an
indispensable role in the malignant progression and metastasis of gastric cancer (GC). As …

Vδ1T cells, a rare subset of γδT cells, hold promise for treating solid tumors. Unlike
conventional T cells, they recognize tumor antigens independently of the MHC antigen …

Abstract While CAR-T and tgTCR-T therapies have exhibited noteworthy and promising
outcomes in hematologic and solid tumors respectively, a set of distinct challenges remains …

In the past decade, a lot of insight was gathered into the composition of the host and tumor
factors that promote oncogenesis and treatment resistance. This in turn has led to the …